The FDA Oncology Center of Excellence (OCE) Pediatric Oncology Program cordially invites members of the pediatric oncology advocacy community to participate in this forum to strengthen collaboration and promote more efficient development of new safe and effective drugs and biological products for pediatric patients with cancer. This forum will fea
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year…
More than 11,000 researchers, clinicians, patient advocates and drugmakers gathered last week at the San Antonio Breast Cancer Symposium to share the latest treatments, tricks…
FDA has issued a final rule to update the “healthy” nutrient content claim to help consumers identify foods that are particularly useful as the foundation…
The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.
Endo, Inc (OTCQX: NDOI) (“Endo”), announced today that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling all lots within expiry of Adrenalin®…
Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.
PURPOSESelpercatinib, a highly selective RET kinase inhibitor with CNS activity, is approved in multiple countries for patients with RET fusion–positive non–small cell lung cancer (NSCLC).METHODSPatients…
This cohort study examines whether osimertinib is associated with a higher incidence of cardiac toxic effects compared with earlier-generation epidermal growth factor receptor tyrosine kinase…
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the new PANGEA 2.0 model, which aims to improve risk stratification of smoldering multiple myeloma (SMM)…
Today, the FDA approved the first medication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
